在CDKL5脑病变中使用抗发作药物 - 系统性审查
Adrianna Kalinowska-Doman1, Adam Strzelczyk2, Justyna Paprocka1
1Pediatric Neurology Department, Medical University of Silesia, Faculty of Medical Sciences, Katowice, Poland.
Seizure
|August 20, 2025
概括
循环素依赖的酶类5缺乏症 (CDD) 治疗仍然具有挑战性. 最近的抗发作药物 (ASM),如 ganaxolone 和 cannabidiol,显示出适度的益处,而性饮食可以减少50%的发作.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 循环素依赖性酶类5缺乏障碍 (CDD) 是一种严重的发育性和性脑病变 (DEE).
- CDD的特点是耐药性,发育迟缓和运动障碍,在90%的病例中表现在生命的第一年内.
- 在CDD中的耐火性需要对有效的抗发作药物 (ASM) 的持续研究.
研究的目的:
- 审查最近关于抗发作药物 (ASM) 治疗CDKL5缺乏障碍 (CDD) 中的疗效的研究.
- 总结了既有和新型ASM的治疗效果,包括 ganaxolone 和 cannabidiol,在CDD患者中.
- 评估辅助疗法的有效性,例如性饮食.
主要方法:
- 在PubMed数据库上对2019年1月至2024年10月期间发表的研究进行了系统的文献搜索.
- 使用的关键词包括"cdkl5"和"cdkl5缺乏症",还在clinicaltrials.gov上搜索临床试验.
- 文献选遵循PRISMA指导方针,根据包含和排除标准进行独立审查.
主要成果:
- 在CDD中治疗仍然很困难,经典的ASM如clobazam,lamotrigine,valproic acid和 vigabatrin表现出不同的成功.
- 通道阻断剂仅在约30%的患者中有效,而 ganaxolone 显示了适度的~30%的发作频率降低.
- 性饮食显示出显著的疗效,约50%降低了发作频率,而Epidyolex (大麻二醇) 显示出可变的益处,特别是在运动发作方面.
结论:
- 目前对CDD的治疗选择有限,因为全球研究的患者数量很少.
- 进一步的大规模,前性研究是必不可少的,以产生关于CDD治疗结果的可靠数据.
- 对ASM疗效的更好理解对于改善CDD治疗策略至关重要.
更多相关视频
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
2.8K
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
696
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274
01:17Antiepileptic Drugs: Calcium Channel Blockers
615
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
615
01:24Epilepsy and Seizures: Overview
277
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
277
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
640
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
640
01:14Antiepileptic Drugs: Glutamate Antagonists
512
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
512
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
446
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
446